Clinical Trial Update: The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial assessing bevacizumab with m-FOLFOXIRI for borderline resectable colorectal liver metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• m-FOLFOXIRI

Snippet

Sponsor: National Cheng-Kung University Hospital | Conditions: Colorectal Cancer | Phase 2 | Status: UNKNOWN